In a Tuesday panel discussion at The American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, representatives from HHS, the National Institutes of Health (NIH), and the CDC outlined ongoing federal initiatives to address the parallel problems of pain and opioid addiction.
In a Tuesday panel discussion at The American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, representatives from HHS, the National Institutes of Health (NIH), and the CDC outlined ongoing federal initiatives to address the parallel problems of pain and opioid addiction.
HHS
Vanila Singh, MD, MACM, chief medical officer of Office of the Assistant Secretary of Health at HHS, began her remarks by itemizing the 5 prongs of HHS’ plan to address the problem of opioid addiction: improving access to treatment and recovery services; promoting the use of overdose-reversing drugs; strengthening the current understanding of the opioid epidemic through public health surveillance; providing support for research on pain and addiction; and advancing better practices for pain management.
In order to address these objectives, HHS convened a conference on pain that developed the National Pain Strategy. The strategy seeks to address the following:
HHS is assembling a Pain Management Task Force to help implement its strategy, and stakeholders, as mandated by Congress, include prescribers, pharmacists, medical organizations, veterans’ organizations, first responders, patients and patient groups, state medical boards, hospital associations, addition community centers, representatives from rural America, and representatives from minority health populations.
NIH
Linda Porter, PhD, director of the Office of Pain Policy at the NIH, explained that the NIH’s current efforts to address pain “…did start because of the opioid crisis, but they’re mostly related to pain, what we know about pain, and how we care for pain. It’s hard to separate the opioid crisis from the pain crisis, but we certainly are riding a wave [of public awareness] right now.”
The NIH is currently engaged in the Federal Pain Research Strategy that is determining priorities for research into pain. Porter reports that the top 5 areas that the NIH deems to be most impactful overall are as follows:
Additionally, the 5 areas believed to be of the greatest near-term value are the following:
Ultimately, “Better-quality pain management is really crucial to helping reduce our reliance on opioids,” said Porter. In global terms, “more than 50% of the global disease burden [has a] contribution of some pain disorder…we have an opioid problem, and we have a pain problem, and we need a balance of how we manage pain and not deny people who need medication for their particular conditions…They need better care and they need safer medications.”
Porter also indicated that the NIH is currently working together with pharma to promote development of safe and effective pain management therapies.
CDC
Chad Helmick, MD, medical epidemiologist arthritis program at the CDC, said that the opioid crisis is “…really a dysfunctional pain management system. Why focus on pain? The numbers tell the story,” he said, reporting that 25.3 million adults (11.2% of the population) in the United States have daily pain, and 14.4 million have severe pain (6.4% of the population). “The system is not working for these people very well.”
Rheumatologic conditions account for a great many cases of pain, says Helmick, who indicated that 50% of adults who have been issued prescriptions for opioids have arthritis. Similarly, current methods of treating pain associated with rheumatic disease are related to the growing problem of opioid addiction: “We have a variety of evidence-based [therapies]” outside of opioids, he said, referring to physical activity, self-management education, and physical therapy, “But we don’t use them.”
The good news, says Helmick, is that there is growing momentum to address both pain and addiction. The Healthy People 2020 initiative has included developmental objectives for pain, including decreasing the prevalence of adults who have high-impact chronic pain, and the 2016 National Health Interview Survey included 2 questions geared toward better understanding the incidence and impact of chronic pain.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
Early Intervention, Targeted Strategies Needed to Improve Disparities, Survival in Patients With IPF
October 17th 2024Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).
Read More